




Reference: Breast Cancer Benefit Definition  
Contact person: Evelyn Thsehla  
Tel: 012 431 0415  
Fax: 0862424821  
E-mail: [e.thsehla@medicalschemes.com](mailto:e.thsehla@medicalschemes.com)  
Date: 13 May 2016

## Circular 32 of 2016: Benefit definition submissions for gastrointestinal cancer

The Council for Medical Schemes (CMS) invites stakeholders to make submissions for colorectal, esophageal, and pancreatic cancer to be considered for the benefit definition project. The benefit definition project is coordinated by the CMS and aims to define the PMB package, as well as to guide the interpretation of the PMB provisions by relevant stakeholders. The benefit definition project follows a process that was first agreed upon in 2010 (see figure 1).

Figure 1: Prescribed minimum benefit definition process



Submissions from different stakeholders can be in the form of a protocol or single intervention (motivation for the inclusion of a pharmaceutical class of drug, surgical procedure, etc.). Single intervention motivations must be accompanied by economic evaluation, where applicable and supporting literature. Condition specific definitions may consist of any of the following:

- Medical goods (pharmaceuticals and prosthesis)
- Professional services
- Ancillary services, such as radiology, pathology
- Relevant codes
- Exclusions
- Rehabilitation services

All relevant stakeholders are invited to make their submissions to Ms. Evelyn Thsehla ([e.thsehla@medicalschemes.com](mailto:e.thsehla@medicalschemes.com)) by 10 June 2016.



Dr Olurotimi Modupe

Acting Senior Manager: Clinical Unit

Council for Medical Schemes